Actively Recruiting
Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study
Led by University Health Network, Toronto · Updated on 2025-05-14
120
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are looking to further our knowledge on disease biology and treatment selection for gastroesophageal adenocarcinoma. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients for the future.
CONDITIONS
Official Title
Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or confirmed localized gastroesophageal adenocarcinoma suitable for curative treatment including surgery, with or without chemotherapy or chemoradiotherapy
- Age 18 years or older
- Eastern Cooperative Group (ECOG) performance status 0-2
- Patients with advanced gastroesophageal cancer diagnosed by histology or radiology
- Patients must have a tumor lesion suitable for core needle biopsy with at least 3 good quality cores obtainable
- Patients must have a measurable lesion according to RECIST 1.1 criteria
- Patients fit enough to safely undergo tumor biopsy
- Life expectancy greater than 90 days
- Patients planning first-line systemic platinum-based chemotherapy or part of a first-line clinical trial
- Normal organ and marrow function within 14 days before biopsy
You will not qualify if you...
- Patients planned for definitive chemoradiation without surgery (Arm 1)
- Any condition that contraindicates participation due to safety or compliance concerns
- Contraindications to tumor biopsy according to standard procedures (Arm 2)
- Prior systemic treatment for advanced or metastatic gastroesophageal cancer
- Current anti-cancer treatment including chemotherapy for another malignancy
- Known brain metastases
- Patients treated with non-platinum first-line chemotherapy
- Uncontrolled intercurrent illness such as active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social issues limiting compliance
- Any condition contraindicating participation due to safety or compliance concerns as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, LM5G2C4
Actively Recruiting
Research Team
F
Frances Allison
CONTACT
Y
Yvonne Bach
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here